- 专利标题： B CELLS GENETICALLY ENGINEERED TO SECRETE FOLLISTATIN AND METHODS OF USING THE SAME TO TREAT FOLLISTATIN-RELATED DISEASES, CONDITIONS, DISORDERS AND TO ENHANCE MUSCLE GROWTH AND STRENGTH
-
申请号： US16981618申请日： 2019-03-18
-
公开(公告)号： US20210047619A1公开(公告)日： 2021-02-18
- 发明人: Matthew Rein SCHOLZ , Eric J. HERBIG , R. Scott MCIVOR
- 申请人： Immusoft Corporation
- 申请人地址： US WA Seattle
- 专利权人： Immusoft Corporation
- 当前专利权人： Immusoft Corporation
- 当前专利权人地址： US WA Seattle
- 国际申请： PCT/US2019/022821 WO 20190318
- 主分类号： C12N5/0781
- IPC分类号： C12N5/0781 ; A61K35/16 ; A61P21/00 ; A61K9/00
摘要：
The present invention relates to methods for administering autologous and/or allogeneic B cells genetically modified to produce a therapeutic agent, such as follistatin. Specifically disclosed are methods for administering a single, maximally effective dose of genetically modified B cells and for administering multiple doses of genetically modified B cells that express follistatin. The compositions and methods disclosed herein are useful for the long-term, in vivo delivery of follistatin.
信息查询
